There is one clinical trial.
This double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study the utility of nebulized furosemide for pulmonary inflammation in Intubated, mechanically ventilated Patients with COVID-19.
Description: Improvement in oxygenation as determined by a standardized PaO2/FiO2 ratioMeasure: Improvement in pulmonary gas exchange Time: Study Day 5
Description: Number of ventilator-free days in the first 28 days after enrollmentMeasure: Requirement for mechanical ventilation Time: Baseline to day 28
Description: All CauseMeasure: Mortality Time: Day 60 post enrollment
Description: Number of days of alive and not requiring supplemental oxygenMeasure: Requirement for supplemental oxygen Time: To day 28 post enrollment
Description: Duration of ICU StayMeasure: Duration of ICU Stay Time: Up to 60 days post enrollment
Description: Length of hospitalizationMeasure: Length of hospitalization Time: Up to 60 days post enrollment
Description: Incidence of serious adverse events: incorporated as trial outcomes, defined a priori, in accordance with guidelines for academic ICU drug trialsMeasure: Adverse events Time: Up to 60 days post enrollment
Description: Adverse events during the nebulization of furosemideMeasure: Inhalation adverse events Time: Up to day 28
Description: Serum levels of furosemide every 7 days until the completion of therapyMeasure: Serum levels of furosemide Time: Up to day 28
Description: Altered electrolytes on routine testing (frequency of hypokalemia (< 3.0 meq/L), hypernatremia (> 150 meq/L) or increased bicarbonate levels (>30 meq/L) during the ICU stayMeasure: Electrolyte abnormalities Time: Up to day 28
Description: Levels of serum inflammatory cytokines (IL-6, IL-8, TNF-α) at baseline prior to first dose of intervention, day 7, and the completion of therapyMeasure: Cytokine levels Time: Up to day 28
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports